New drug approvals for 2021: Synthesis and clinical applications.
Chemical synthesis
Clinical applications
New drugs
Journal
European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510
Informations de publication
Date de publication:
05 Jan 2023
05 Jan 2023
Historique:
received:
28
09
2022
revised:
27
10
2022
accepted:
31
10
2022
pubmed:
13
11
2022
medline:
6
12
2022
entrez:
12
11
2022
Statut:
ppublish
Résumé
50 New drugs including 36 chemical entities and 14 biologics were approved by the U.S. Food and Drug Administration during 2021. Among the marketed drugs, 31 new small molecule agents (29 small molecule drugs and 2 diagnostic agents) with privileged structures and novel clinical applications represent as promising leads for the development of new drugs with the similar indications and improved therapeutic efficacy. This review is mainly focused on the clinical applications and synthetic methods of 29 small molecule drugs newly approved by the FDA in 2021. We believed that insight into the synthetic approaches of drug molecules would provide creative and practical inspirations for the development of more efficient and practical synthetic technologies to meet with new drug discovery.
Identifiants
pubmed: 36370552
pii: S0223-5234(22)00800-5
doi: 10.1016/j.ejmech.2022.114898
pii:
doi:
Substances chimiques
Biological Products
0
Pharmaceutical Preparations
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
114898Informations de copyright
Copyright © 2022 Elsevier Masson SAS. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.